Blood Biomarkers for Early Dementia Detection & Staging
Key Questions
Which biomarkers form the new blood test for early dementia?
The test uses p-tau217, GFAP, and neurofilament light chain to track progression. It also differentiates Alzheimer's from frontotemporal dementia.
How does the p-tau217 blood test compare to PET scans?
A p-tau217-based test matches PET scan accuracy for Alzheimer's staging. Its practicality supports wider clinical adoption and earlier intervention.
Why are blood biomarkers important for age-related neurodegeneration?
They enable scalable, non-invasive detection of early dementia changes. This supports timely healthspan interventions before advanced symptoms appear.
New blood test using p-tau217, GFAP, and neurofilament light chain predicts early-onset dementia progression and distinguishes Alzheimer's from frontotemporal dementia. Another new blood test using p-tau217 plus another biomarker matches PET scan accuracy for Alzheimer's staging, practical for scaling diagnosis. A new study found Alzheimer's pathology detectable in midlife via blood p-tau217/amyloid ratio, with 6% positivity in 61-year-olds and associated cognitive decline over 5 years. Practical diagnostic advances for age-related neurodegeneration, directly relevant to healthspan and early intervention.